Author

A. Loboda

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 3 Assay:bulk RNA-seq· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

C. Zhang· 2 shared A. A. Sharma· 1 shared A. Banito· 1 shared A. Butsyk· 1 shared A. Byford· 1 shared A. C. N. Sim· 1 shared A. Chandramohan· 1 shared A. Ehlers· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Zhang

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Helicobacter pylori attachment-blocking antibodies protect against duodenal ulcer disease

T. Boren, J. A. Bugaytsova, K. Moonens, A. Piddubnyi, A. Schmidt, J. O. Edlund, G. Lisiutin, K. Brannstrom, Y. A. Chernov, K. Thorell, I. Tkachenko, O. Sharova, I. Vikhrova, A. Butsyk, P. Shubin, , P. Aro

The paper shows that antibodies blocking H. pylori attachment reduce chronic inflammation and duodenal ulcer risk by mimicking BabA's binding to ABO glycans.

bioRxiv · May 24, 2023 · PreprintImmunology

Chromosome 8 gain drives cancer progression by hijacking the translation factor 4E-BP1 sensitizing for targeted CDK4/6 inhibition

C. M. Funk, A. Ehlers, M. F. Orth, K. Aljakouch, J. Li, T. L. B. Hoelting, R. Will, A. K. Ceranski, F. Willis, E. Vinca, S. Ohmura, R. Imle, J. Siebenlist, A. Yershova, M. M. L. Knott, , J. Musa

This study identifies chr8 gains and 4E-BP1 expression as prognostic markers in Ewing sarcoma, showing they drive cancer progression by promoting proliferation and sensitizing to CDK4/6 inhibitors.

bioRxiv · Dec 11, 2022 · PreprintCancer Biology

Antibodies to ILT3 abrogate myeloid immunosuppression and enable tumor killing

P. E. Brandish, A. Palmieri, G. Ayanoglu, J. Baker, R. Bueno, A. Byford, M. Caniga, C. Chappell, H. Cherwinski, D. J. Cua, X. Du, L. Fayadat-Dilman, B. E. Hall, H. Issafras, B. Joyce-Shaikh, , J. Zhang-Hoover

This study shows anti-ILT3 antibodies block myeloid immunosuppression and enhance tumor killing in solid tumors.

bioRxiv · Dec 18, 2021 · PreprintCancer Biology

Microbiome and Metabolome driven differentiation of TGF-beta producing Tregs leads to Senescence and HIV latency

K. Ghneim, A. A. Sharma, S. P. Ribeiro, S. Fourati, J. Ahlers, D. Kulpa, X. Xu, J. Brehm, A. Talla, S. Arumugam, S. Darko, B. Rodriguez, C. Shive, R. Cristescu, A. Loboda, , R.-P. Sekaly

The paper identifies cellular senescence and TGF-beta pathways in HIV-infected individuals that contribute to HIV latency and poor immune recovery, suggesting potential therapeutic targets.

bioRxiv · Dec 15, 2020 · PreprintImmunology

STUB1 is an intracellular checkpoint for interferon gamma sensing

S. Ng, S. Lim, A. C. N. Sim, R. Mangadu, A. Lau, C. Zhang, S. Bollinger Martinez, A. Chandramohan, U.-M. Lim, S. S. W. Ho, S. C. Chang, P. Gopal, L. Z. Hong, A. Schwaid, A. Z. Fernandis, , A. W. Partridge

This study identifies STUB1 as a barrier to interferon gamma sensing, showing it dampens IFNγ response through reduced IFNGR1 surface abundance, but in vivo STUB1 inactivation did not improve ICB outcomes in mouse models.

bioRxiv · Dec 14, 2020Cancer Biology